Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$591.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Moshe Arkin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Beta
- 1.15
- Country
- IL
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 18.56
Financials
Revenue
$591.0K+239.7%Net Income
$-3.68MEBITDA
$-4.16MFree Cash Flow
—EPS (diluted)
$-1.13Shares Outstanding (diluted)
3.27M-81.8%Operating Expenses
$4.75MCash & Debt
$47.93MReturn of Capital
$0.00Revenue by Segment (annual)
$19.39MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $19.39M | $-6.13M | $-2.20 |
| 2024 | $11.54M | $-10.58M | $-3.79 |
| 2023 | $1.55M | $-27.24M | $-10.01 |
| 2022 | $3.88M | $-14.92M | $-0.65 |
| 2021 | $31.27M | $3.22M | $1.40 |
| 2020 | $8.77M | $-29.29M | $-1.30 |
| 2019 | $22.90M | $-24.61M | $-1.26 |
| 2018 | $129.0K | $-32.20M | $-1.80 |
| 2017 | $174.0K | $-31.57M | $-1.76 |
| 2016 | $0.00 | $-20.77M | $-1.77 |
| 2015 | $0.00 | $-9.66M | $-0.82 |
| 2014 | $0.00 | $-4.85M | $-1.81 |
Valuation
SLGLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
127+26.67%Social Signal Score
Mentions (3)
- Newszacks.com·5h ago·Positive
SolGel Technologies (SLGL) Upgraded to Buy: Here's Why SolGel Technologies (SLGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·21d ago·Neutral
SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? SolGel Technologies (SLGL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
View source ↗ - Newsglobenewswire.com·49d ago·Neutral
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates NESS ZIONA, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.
View source ↗
Earnings
Thu, Nov 19(in 6 weeks)
Consensus estimate $-2.27 per share
Typical surprise -1.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 20$-1.13 vs $-2.36beat
- Thu, May 28$-1.31 vs $-2.86beat
- Thu, Mar 19$-1.07 vs $0.39miss
- Thu, Nov 20$-2.13 vs $-2.09miss
- Fri, Aug 15$4.17 vs $-0.67beat
- Mon, May 19$-3.20 vs $-1.25miss
Estimates and results for SLGL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SLGL officers and directors.
- Bought
- $11.2m
- Sold
- —
49 trades
0 trades
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
- Opaleye Management Inc.bought
36 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SLGL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.